NOAC Portuguese Real World Study
Conditions: Stroke; Systemic Embolism; Major Bleeding Interventions: Drug: Apixaban; Drug: dabigatran; Drug: rivaroxaban; Drug: VKAs Sponsor: Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 22, 2021 Category: Research Source Type: clinical trials
A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects
Condition: Acute Ischemic Stroke Interventions: Drug: LT3001 drug product; Drug: Placebo; Drug: Aspirin; Drug: Clopidogrel; Drug: Apixaban; Drug: Dabigatran Sponsor: Lumosa Therapeutics Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 22, 2021 Category: Research Source Type: clinical trials
NOAC Portuguese Real World Study
Conditions: Stroke; Systemic Embolism; Major Bleeding Interventions: Drug: Apixaban; Drug: dabigatran; Drug: rivaroxaban; Drug: VKAs Sponsor: Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 22, 2021 Category: Research Source Type: clinical trials
A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects
Condition: Acute Ischemic Stroke Interventions: Drug: LT3001 drug product; Drug: Placebo; Drug: Aspirin; Drug: Clopidogrel; Drug: Apixaban; Drug: Dabigatran Sponsor: Lumosa Therapeutics Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 22, 2021 Category: Research Source Type: clinical trials
NOAC Portuguese Real World Study
Conditions: Stroke; Systemic Embolism; Major Bleeding Interventions: Drug: Apixaban; Drug: dabigatran; Drug: rivaroxaban; Drug: VKAs Sponsor: Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 22, 2021 Category: Research Source Type: clinical trials
A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects
Condition: Acute Ischemic Stroke Interventions: Drug: LT3001 drug product; Drug: Placebo; Drug: Aspirin; Drug: Clopidogrel; Drug: Apixaban; Drug: Dabigatran Sponsor: Lumosa Therapeutics Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 22, 2021 Category: Research Source Type: clinical trials
NOAC Portuguese Real World Study
Conditions: Stroke; Systemic Embolism; Major Bleeding Interventions: Drug: Apixaban; Drug: dabigatran; Drug: rivaroxaban; Drug: VKAs Sponsor: Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 22, 2021 Category: Research Source Type: clinical trials
Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG – RAPID Trial): A structured summary of a study protocol for a randomised controlled trial
AbstractObjectivesTo determine the effect of therapeutic anticoagulation, with low molecular weight heparin (LMWH) or unfractionated heparin (UFH, high dose nomogram), compared to standard care in hospitalized patients admitted for COVID-19 with an elevated D-dimer on the composite outcome of intensive care unit (ICU) admission, non-invasive positive pressure ventilation, invasive mechanical ventilation or death up to 28 days.Trial designOpen-label, parallel, 1:1, phase 3, 2-arm randomized controlled trialParticipantsThe study population includes hospitalized adults admitted for COVID-19 prior to the development of critica...
Source: Trials - March 10, 2021 Category: Research Source Type: clinical trials
A Drug Drug Interaction (DDI) Study of Selpercatinib and Dabigatran in Healthy Participants
Condition: Healthy Interventions: Drug: Dabigatran; Drug: Selpercatinib Sponsors: Eli Lilly and Company; Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 4, 2021 Category: Research Source Type: clinical trials
